Alar Pharmaceuticals Inc. (TPEX: 6785)
Taiwan
· Delayed Price · Currency is TWD
152.00
+0.50 (0.33%)
Nov 22, 2024, 1:30 PM CST
Alar Pharmaceuticals Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2017 |
---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2017 |
Cash & Equivalents | 950.73 | 739.46 | 455.35 | 519.07 | 560.96 | 49.45 | Upgrade
|
Short-Term Investments | 1,474 | 156.53 | 30.87 | - | - | 121.8 | Upgrade
|
Cash & Short-Term Investments | 2,424 | 895.99 | 486.22 | 519.07 | 560.96 | 171.25 | Upgrade
|
Cash Growth | 293.08% | 84.28% | -6.33% | -7.47% | 227.56% | -31.38% | Upgrade
|
Receivables | - | - | 0.84 | - | - | - | Upgrade
|
Prepaid Expenses | 1.51 | 3.56 | 9.96 | 9.62 | 7.7 | 5.7 | Upgrade
|
Other Current Assets | 10.46 | 3.47 | 0.55 | 0.01 | 22.76 | 6.77 | Upgrade
|
Total Current Assets | 2,436 | 903.02 | 497.57 | 528.69 | 591.42 | 183.72 | Upgrade
|
Property, Plant & Equipment | 12.9 | 12.77 | 9.78 | 9.1 | 7.75 | 10.21 | Upgrade
|
Long-Term Deferred Tax Assets | 48.09 | 54.97 | 13 | - | - | - | Upgrade
|
Other Long-Term Assets | 0.46 | 2.45 | 2.25 | 2.11 | 4.8 | 2.03 | Upgrade
|
Total Assets | 2,523 | 973.21 | 522.6 | 539.91 | 603.98 | 195.97 | Upgrade
|
Accounts Payable | - | - | - | - | - | 0.15 | Upgrade
|
Accrued Expenses | - | 19.76 | 2.02 | 2.17 | 2 | 1.46 | Upgrade
|
Current Portion of Leases | 0.34 | 1.27 | 1.29 | 0.68 | 0.91 | 0.89 | Upgrade
|
Current Income Taxes Payable | 47.77 | 49.45 | - | - | - | - | Upgrade
|
Current Unearned Revenue | 1.25 | 1.25 | - | - | - | - | Upgrade
|
Other Current Liabilities | 4.61 | 3.04 | 2.06 | 1.61 | 1.22 | 0.91 | Upgrade
|
Total Current Liabilities | 53.98 | 74.77 | 5.37 | 4.46 | 4.13 | 3.41 | Upgrade
|
Long-Term Leases | 0.09 | 0.14 | 1.41 | 0.27 | 0.61 | 1.52 | Upgrade
|
Long-Term Deferred Tax Liabilities | 0.44 | - | 0.33 | - | - | - | Upgrade
|
Other Long-Term Liabilities | 1.43 | 1.18 | 0.99 | 0.81 | 0.63 | - | Upgrade
|
Total Liabilities | 55.93 | 76.09 | 8.1 | 5.54 | 5.37 | 4.93 | Upgrade
|
Common Stock | 668 | 570 | 570 | 570 | 570 | 350 | Upgrade
|
Additional Paid-In Capital | 1,579 | - | - | 424.04 | 424.04 | 93.68 | Upgrade
|
Retained Earnings | 220.21 | 327.12 | -55.5 | -459.67 | -395.44 | -252.64 | Upgrade
|
Shareholders' Equity | 2,467 | 897.12 | 514.5 | 534.37 | 598.6 | 191.04 | Upgrade
|
Total Liabilities & Equity | 2,523 | 973.21 | 522.6 | 539.91 | 603.98 | 195.97 | Upgrade
|
Total Debt | 0.42 | 1.41 | 2.69 | 0.95 | 1.52 | 2.41 | Upgrade
|
Net Cash (Debt) | 2,424 | 894.58 | 483.53 | 518.12 | 559.44 | 168.85 | Upgrade
|
Net Cash Growth | 294.12% | 85.01% | -6.68% | -7.39% | 231.33% | -32.35% | Upgrade
|
Net Cash Per Share | 36.38 | 15.68 | 8.48 | 9.09 | 11.21 | 4.82 | Upgrade
|
Filing Date Shares Outstanding | 69.17 | 57 | 57 | 57 | 57 | 57 | Upgrade
|
Total Common Shares Outstanding | 69.17 | 57 | 57 | 57 | 57 | 35 | Upgrade
|
Working Capital | 2,382 | 828.25 | 492.2 | 524.24 | 587.3 | 180.32 | Upgrade
|
Book Value Per Share | 35.66 | 15.74 | 9.03 | 9.37 | 10.50 | 5.46 | Upgrade
|
Tangible Book Value | 2,467 | 897.12 | 514.5 | 534.37 | 598.6 | 191.04 | Upgrade
|
Tangible Book Value Per Share | 35.66 | 15.74 | 9.03 | 9.37 | 10.50 | 5.46 | Upgrade
|
Machinery | - | 22.99 | 16.65 | 16.42 | 12.07 | 11.69 | Upgrade
|
Leasehold Improvements | - | 0.98 | 0.98 | 1.05 | 1.05 | 1.05 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.